Disc Medicine shares are exploding higher following the announcement of positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria. The company reported early Monday that the trial successfully met all primary and secondary endpoints, including a reduction in protoporphyrin IX levels and increased total time in light for patients. Following this clinical success, management confirmed plans to resubmit the drug for FDA approval by the end of the year, a move that has significantly bolstered investor confidence in the company's lead asset.